spr experiments Search Results


90
Biaffin Inc spr experiments
Spr Experiments, supplied by Biaffin Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spr+experiments/spr+experiments/pmc03090414-126-1-7
Average 90 stars, based on 1 article reviews
spr experiments - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Sensiq Technologies spr experiment
Spr Experiment, supplied by Sensiq Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spr+experiments/spr+experiment/10__1074_slash_jbc__m115__678359-238-47-42
Average 90 stars, based on 1 article reviews
spr experiment - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Biacore spr experiments
Spr Experiments, supplied by Biacore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spr+experiments/spr+experiments/pm15893292-56-1-7
Average 90 stars, based on 1 article reviews
spr experiments - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Biacore spr adsorption experiments
Response curves <t>(SPR</t> signal (RU) vs time for TGTG-A-GTGT on CH3–SAMs at 25° showing an irreversible <t>adsorption</t> process even for this small peptide. The large drop in the SPR response when pure buffer was introduced at 90 s is primarily due to the bulk-shift effect.
Spr Adsorption Experiments, supplied by Biacore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spr+experiments/spr+adsorption+experiments/pmc02638991-159-0-11
Average 90 stars, based on 1 article reviews
spr adsorption experiments - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Biacore spr binding experiments
<t>(A)</t> <t>Biacore</t> <t>SPR</t> analysis of in vitro RafRBD binding: K-Ras-GTP or K-Ras-GDP (10 µM) were injected over WT- or R89L-RafRBD and binding responses were determined. (B) A 2-fold dilution series of Rigosertib (50 µM to 0.39 µM) was injected over WT-RafRBD and binding was determined by SPR. (C) 5 µM WT-RafRBD was mixed with increasing concentrations of Rigosertib (0.19 – 50 µM), following which binding to avi-K-RasGTP was measured (red lines) and compared to a RafRBD calibration series (black lines) (D) WT- or R89L-GST-RafRBD was incubated for 1 hr with increasing concentrations of Rigosertib and binding to GTP-loaded WTor G12V-K-Ras was determined by proximity based energy transfer. As a control for nonspecific inhibition, the effect of Rigosertib on Avi-GST was also monitored. (E) HeLa cells were treated as indicated with DMSO or 2 µM Rigosertib (Rig) prior to stimulation with EGF for 5 min (+) and lysis. Raf dimerization was monitored by probing Raf immunoprecipitates for the presence of other Raf family members. Lysates were examined for activated pMEK, pERK, and pAKT levels and for total B-Raf, C-Raf, A-Raf and tubulin (loading control) levels. (F) Depiction of the Raf domain structure and location of the Rigosertib-induced sites of S/TP phosphorylation. (G) The indicated cancer lines were treated with DMSO (−) or Rigosertib (+) for 18 hrs prior to lysis. Endogenous C-Raf was immunoprecipitated and probed for pS642P levels or B-Raf. Shifts in the electrophoretic mobility of B-Raf and C-Raf were also examined.
Spr Binding Experiments, supplied by Biacore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spr+experiments/spr+binding+experiments/pmc05135640-343-0-7
Average 90 stars, based on 1 article reviews
spr binding experiments - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Biacore spr binding experiments biacore 2000 instrument
<t>(A)</t> <t>Biacore</t> <t>SPR</t> analysis of in vitro RafRBD binding: K-Ras-GTP or K-Ras-GDP (10 µM) were injected over WT- or R89L-RafRBD and binding responses were determined. (B) A 2-fold dilution series of Rigosertib (50 µM to 0.39 µM) was injected over WT-RafRBD and binding was determined by SPR. (C) 5 µM WT-RafRBD was mixed with increasing concentrations of Rigosertib (0.19 – 50 µM), following which binding to avi-K-RasGTP was measured (red lines) and compared to a RafRBD calibration series (black lines) (D) WT- or R89L-GST-RafRBD was incubated for 1 hr with increasing concentrations of Rigosertib and binding to GTP-loaded WTor G12V-K-Ras was determined by proximity based energy transfer. As a control for nonspecific inhibition, the effect of Rigosertib on Avi-GST was also monitored. (E) HeLa cells were treated as indicated with DMSO or 2 µM Rigosertib (Rig) prior to stimulation with EGF for 5 min (+) and lysis. Raf dimerization was monitored by probing Raf immunoprecipitates for the presence of other Raf family members. Lysates were examined for activated pMEK, pERK, and pAKT levels and for total B-Raf, C-Raf, A-Raf and tubulin (loading control) levels. (F) Depiction of the Raf domain structure and location of the Rigosertib-induced sites of S/TP phosphorylation. (G) The indicated cancer lines were treated with DMSO (−) or Rigosertib (+) for 18 hrs prior to lysis. Endogenous C-Raf was immunoprecipitated and probed for pS642P levels or B-Raf. Shifts in the electrophoretic mobility of B-Raf and C-Raf were also examined.
Spr Binding Experiments Biacore 2000 Instrument, supplied by Biacore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spr+experiments/spr+binding+experiments+biacore+2000+instrument/pmc08185552-281-5-7
Average 90 stars, based on 1 article reviews
spr binding experiments biacore 2000 instrument - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Inhibitex spr experiments
<t>(A)</t> <t>Biacore</t> <t>SPR</t> analysis of in vitro RafRBD binding: K-Ras-GTP or K-Ras-GDP (10 µM) were injected over WT- or R89L-RafRBD and binding responses were determined. (B) A 2-fold dilution series of Rigosertib (50 µM to 0.39 µM) was injected over WT-RafRBD and binding was determined by SPR. (C) 5 µM WT-RafRBD was mixed with increasing concentrations of Rigosertib (0.19 – 50 µM), following which binding to avi-K-RasGTP was measured (red lines) and compared to a RafRBD calibration series (black lines) (D) WT- or R89L-GST-RafRBD was incubated for 1 hr with increasing concentrations of Rigosertib and binding to GTP-loaded WTor G12V-K-Ras was determined by proximity based energy transfer. As a control for nonspecific inhibition, the effect of Rigosertib on Avi-GST was also monitored. (E) HeLa cells were treated as indicated with DMSO or 2 µM Rigosertib (Rig) prior to stimulation with EGF for 5 min (+) and lysis. Raf dimerization was monitored by probing Raf immunoprecipitates for the presence of other Raf family members. Lysates were examined for activated pMEK, pERK, and pAKT levels and for total B-Raf, C-Raf, A-Raf and tubulin (loading control) levels. (F) Depiction of the Raf domain structure and location of the Rigosertib-induced sites of S/TP phosphorylation. (G) The indicated cancer lines were treated with DMSO (−) or Rigosertib (+) for 18 hrs prior to lysis. Endogenous C-Raf was immunoprecipitated and probed for pS642P levels or B-Raf. Shifts in the electrophoretic mobility of B-Raf and C-Raf were also examined.
Spr Experiments, supplied by Inhibitex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spr+experiments/spr+experiments/pmc03485874-452-26-3
Average 90 stars, based on 1 article reviews
spr experiments - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Verlag GmbH surface plasmon resonance (spr) experiments
<t>(A)</t> <t>Biacore</t> <t>SPR</t> analysis of in vitro RafRBD binding: K-Ras-GTP or K-Ras-GDP (10 µM) were injected over WT- or R89L-RafRBD and binding responses were determined. (B) A 2-fold dilution series of Rigosertib (50 µM to 0.39 µM) was injected over WT-RafRBD and binding was determined by SPR. (C) 5 µM WT-RafRBD was mixed with increasing concentrations of Rigosertib (0.19 – 50 µM), following which binding to avi-K-RasGTP was measured (red lines) and compared to a RafRBD calibration series (black lines) (D) WT- or R89L-GST-RafRBD was incubated for 1 hr with increasing concentrations of Rigosertib and binding to GTP-loaded WTor G12V-K-Ras was determined by proximity based energy transfer. As a control for nonspecific inhibition, the effect of Rigosertib on Avi-GST was also monitored. (E) HeLa cells were treated as indicated with DMSO or 2 µM Rigosertib (Rig) prior to stimulation with EGF for 5 min (+) and lysis. Raf dimerization was monitored by probing Raf immunoprecipitates for the presence of other Raf family members. Lysates were examined for activated pMEK, pERK, and pAKT levels and for total B-Raf, C-Raf, A-Raf and tubulin (loading control) levels. (F) Depiction of the Raf domain structure and location of the Rigosertib-induced sites of S/TP phosphorylation. (G) The indicated cancer lines were treated with DMSO (−) or Rigosertib (+) for 18 hrs prior to lysis. Endogenous C-Raf was immunoprecipitated and probed for pS642P levels or B-Raf. Shifts in the electrophoretic mobility of B-Raf and C-Raf were also examined.
Surface Plasmon Resonance (Spr) Experiments, supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spr+experiments/surface+plasmon+resonance++spr++experiments/pm23868291-65-22-2
Average 90 stars, based on 1 article reviews
surface plasmon resonance (spr) experiments - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Biacore biacore spr experiment
<t>(A)</t> <t>Biacore</t> <t>SPR</t> analysis of in vitro RafRBD binding: K-Ras-GTP or K-Ras-GDP (10 µM) were injected over WT- or R89L-RafRBD and binding responses were determined. (B) A 2-fold dilution series of Rigosertib (50 µM to 0.39 µM) was injected over WT-RafRBD and binding was determined by SPR. (C) 5 µM WT-RafRBD was mixed with increasing concentrations of Rigosertib (0.19 – 50 µM), following which binding to avi-K-RasGTP was measured (red lines) and compared to a RafRBD calibration series (black lines) (D) WT- or R89L-GST-RafRBD was incubated for 1 hr with increasing concentrations of Rigosertib and binding to GTP-loaded WTor G12V-K-Ras was determined by proximity based energy transfer. As a control for nonspecific inhibition, the effect of Rigosertib on Avi-GST was also monitored. (E) HeLa cells were treated as indicated with DMSO or 2 µM Rigosertib (Rig) prior to stimulation with EGF for 5 min (+) and lysis. Raf dimerization was monitored by probing Raf immunoprecipitates for the presence of other Raf family members. Lysates were examined for activated pMEK, pERK, and pAKT levels and for total B-Raf, C-Raf, A-Raf and tubulin (loading control) levels. (F) Depiction of the Raf domain structure and location of the Rigosertib-induced sites of S/TP phosphorylation. (G) The indicated cancer lines were treated with DMSO (−) or Rigosertib (+) for 18 hrs prior to lysis. Endogenous C-Raf was immunoprecipitated and probed for pS642P levels or B-Raf. Shifts in the electrophoretic mobility of B-Raf and C-Raf were also examined.
Biacore Spr Experiment, supplied by Biacore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spr+experiments/biacore+spr+experiments/us10738131-2977-8-7
Average 90 stars, based on 1 article reviews
biacore spr experiment - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Biacore spr-based biacorex biosensor
<t>(A)</t> <t>Biacore</t> <t>SPR</t> analysis of in vitro RafRBD binding: K-Ras-GTP or K-Ras-GDP (10 µM) were injected over WT- or R89L-RafRBD and binding responses were determined. (B) A 2-fold dilution series of Rigosertib (50 µM to 0.39 µM) was injected over WT-RafRBD and binding was determined by SPR. (C) 5 µM WT-RafRBD was mixed with increasing concentrations of Rigosertib (0.19 – 50 µM), following which binding to avi-K-RasGTP was measured (red lines) and compared to a RafRBD calibration series (black lines) (D) WT- or R89L-GST-RafRBD was incubated for 1 hr with increasing concentrations of Rigosertib and binding to GTP-loaded WTor G12V-K-Ras was determined by proximity based energy transfer. As a control for nonspecific inhibition, the effect of Rigosertib on Avi-GST was also monitored. (E) HeLa cells were treated as indicated with DMSO or 2 µM Rigosertib (Rig) prior to stimulation with EGF for 5 min (+) and lysis. Raf dimerization was monitored by probing Raf immunoprecipitates for the presence of other Raf family members. Lysates were examined for activated pMEK, pERK, and pAKT levels and for total B-Raf, C-Raf, A-Raf and tubulin (loading control) levels. (F) Depiction of the Raf domain structure and location of the Rigosertib-induced sites of S/TP phosphorylation. (G) The indicated cancer lines were treated with DMSO (−) or Rigosertib (+) for 18 hrs prior to lysis. Endogenous C-Raf was immunoprecipitated and probed for pS642P levels or B-Raf. Shifts in the electrophoretic mobility of B-Raf and C-Raf were also examined.
Spr Based Biacorex Biosensor, supplied by Biacore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spr+experiments/spr+experiments+biacore+x/10__1074_slash_jbc__m403170200-58-15-0
Average 90 stars, based on 1 article reviews
spr-based biacorex biosensor - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
KU Leuven spr experiments
<t>(A)</t> <t>Biacore</t> <t>SPR</t> analysis of in vitro RafRBD binding: K-Ras-GTP or K-Ras-GDP (10 µM) were injected over WT- or R89L-RafRBD and binding responses were determined. (B) A 2-fold dilution series of Rigosertib (50 µM to 0.39 µM) was injected over WT-RafRBD and binding was determined by SPR. (C) 5 µM WT-RafRBD was mixed with increasing concentrations of Rigosertib (0.19 – 50 µM), following which binding to avi-K-RasGTP was measured (red lines) and compared to a RafRBD calibration series (black lines) (D) WT- or R89L-GST-RafRBD was incubated for 1 hr with increasing concentrations of Rigosertib and binding to GTP-loaded WTor G12V-K-Ras was determined by proximity based energy transfer. As a control for nonspecific inhibition, the effect of Rigosertib on Avi-GST was also monitored. (E) HeLa cells were treated as indicated with DMSO or 2 µM Rigosertib (Rig) prior to stimulation with EGF for 5 min (+) and lysis. Raf dimerization was monitored by probing Raf immunoprecipitates for the presence of other Raf family members. Lysates were examined for activated pMEK, pERK, and pAKT levels and for total B-Raf, C-Raf, A-Raf and tubulin (loading control) levels. (F) Depiction of the Raf domain structure and location of the Rigosertib-induced sites of S/TP phosphorylation. (G) The indicated cancer lines were treated with DMSO (−) or Rigosertib (+) for 18 hrs prior to lysis. Endogenous C-Raf was immunoprecipitated and probed for pS642P levels or B-Raf. Shifts in the electrophoretic mobility of B-Raf and C-Raf were also examined.
Spr Experiments, supplied by KU Leuven, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spr+experiments/spr+experiments/pm25462225-145-6-11
Average 90 stars, based on 1 article reviews
spr experiments - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
BioCore Inc biocore spr experiment
<t>(A)</t> <t>Biacore</t> <t>SPR</t> analysis of in vitro RafRBD binding: K-Ras-GTP or K-Ras-GDP (10 µM) were injected over WT- or R89L-RafRBD and binding responses were determined. (B) A 2-fold dilution series of Rigosertib (50 µM to 0.39 µM) was injected over WT-RafRBD and binding was determined by SPR. (C) 5 µM WT-RafRBD was mixed with increasing concentrations of Rigosertib (0.19 – 50 µM), following which binding to avi-K-RasGTP was measured (red lines) and compared to a RafRBD calibration series (black lines) (D) WT- or R89L-GST-RafRBD was incubated for 1 hr with increasing concentrations of Rigosertib and binding to GTP-loaded WTor G12V-K-Ras was determined by proximity based energy transfer. As a control for nonspecific inhibition, the effect of Rigosertib on Avi-GST was also monitored. (E) HeLa cells were treated as indicated with DMSO or 2 µM Rigosertib (Rig) prior to stimulation with EGF for 5 min (+) and lysis. Raf dimerization was monitored by probing Raf immunoprecipitates for the presence of other Raf family members. Lysates were examined for activated pMEK, pERK, and pAKT levels and for total B-Raf, C-Raf, A-Raf and tubulin (loading control) levels. (F) Depiction of the Raf domain structure and location of the Rigosertib-induced sites of S/TP phosphorylation. (G) The indicated cancer lines were treated with DMSO (−) or Rigosertib (+) for 18 hrs prior to lysis. Endogenous C-Raf was immunoprecipitated and probed for pS642P levels or B-Raf. Shifts in the electrophoretic mobility of B-Raf and C-Raf were also examined.
Biocore Spr Experiment, supplied by BioCore Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spr+experiments/biocore+spr+experiment/us10752703-2988-8-7
Average 90 stars, based on 1 article reviews
biocore spr experiment - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Response curves (SPR signal (RU) vs time for TGTG-A-GTGT on CH3–SAMs at 25° showing an irreversible adsorption process even for this small peptide. The large drop in the SPR response when pure buffer was introduced at 90 s is primarily due to the bulk-shift effect.

Journal:

Article Title: Determination of the Adsorption Free Energy for Peptide-Surface Interactions by SPR Spectroscopy

doi: 10.1021/la8005772

Figure Lengend Snippet: Response curves (SPR signal (RU) vs time for TGTG-A-GTGT on CH3–SAMs at 25° showing an irreversible adsorption process even for this small peptide. The large drop in the SPR response when pure buffer was introduced at 90 s is primarily due to the bulk-shift effect.

Article Snippet: SPR Adsorption Experiments Adsorption experiments were conducted by SPR using a Biacore × instrument (Biacore, Inc., Piscataway, NJ).

Techniques: Adsorption

(A) Biacore SPR analysis of in vitro RafRBD binding: K-Ras-GTP or K-Ras-GDP (10 µM) were injected over WT- or R89L-RafRBD and binding responses were determined. (B) A 2-fold dilution series of Rigosertib (50 µM to 0.39 µM) was injected over WT-RafRBD and binding was determined by SPR. (C) 5 µM WT-RafRBD was mixed with increasing concentrations of Rigosertib (0.19 – 50 µM), following which binding to avi-K-RasGTP was measured (red lines) and compared to a RafRBD calibration series (black lines) (D) WT- or R89L-GST-RafRBD was incubated for 1 hr with increasing concentrations of Rigosertib and binding to GTP-loaded WTor G12V-K-Ras was determined by proximity based energy transfer. As a control for nonspecific inhibition, the effect of Rigosertib on Avi-GST was also monitored. (E) HeLa cells were treated as indicated with DMSO or 2 µM Rigosertib (Rig) prior to stimulation with EGF for 5 min (+) and lysis. Raf dimerization was monitored by probing Raf immunoprecipitates for the presence of other Raf family members. Lysates were examined for activated pMEK, pERK, and pAKT levels and for total B-Raf, C-Raf, A-Raf and tubulin (loading control) levels. (F) Depiction of the Raf domain structure and location of the Rigosertib-induced sites of S/TP phosphorylation. (G) The indicated cancer lines were treated with DMSO (−) or Rigosertib (+) for 18 hrs prior to lysis. Endogenous C-Raf was immunoprecipitated and probed for pS642P levels or B-Raf. Shifts in the electrophoretic mobility of B-Raf and C-Raf were also examined.

Journal: Molecular cell

Article Title: Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-induced Phospho-regulatory Circuit

doi: 10.1016/j.molcel.2016.10.029

Figure Lengend Snippet: (A) Biacore SPR analysis of in vitro RafRBD binding: K-Ras-GTP or K-Ras-GDP (10 µM) were injected over WT- or R89L-RafRBD and binding responses were determined. (B) A 2-fold dilution series of Rigosertib (50 µM to 0.39 µM) was injected over WT-RafRBD and binding was determined by SPR. (C) 5 µM WT-RafRBD was mixed with increasing concentrations of Rigosertib (0.19 – 50 µM), following which binding to avi-K-RasGTP was measured (red lines) and compared to a RafRBD calibration series (black lines) (D) WT- or R89L-GST-RafRBD was incubated for 1 hr with increasing concentrations of Rigosertib and binding to GTP-loaded WTor G12V-K-Ras was determined by proximity based energy transfer. As a control for nonspecific inhibition, the effect of Rigosertib on Avi-GST was also monitored. (E) HeLa cells were treated as indicated with DMSO or 2 µM Rigosertib (Rig) prior to stimulation with EGF for 5 min (+) and lysis. Raf dimerization was monitored by probing Raf immunoprecipitates for the presence of other Raf family members. Lysates were examined for activated pMEK, pERK, and pAKT levels and for total B-Raf, C-Raf, A-Raf and tubulin (loading control) levels. (F) Depiction of the Raf domain structure and location of the Rigosertib-induced sites of S/TP phosphorylation. (G) The indicated cancer lines were treated with DMSO (−) or Rigosertib (+) for 18 hrs prior to lysis. Endogenous C-Raf was immunoprecipitated and probed for pS642P levels or B-Raf. Shifts in the electrophoretic mobility of B-Raf and C-Raf were also examined.

Article Snippet: SPR binding experiments were performed on a Biacore S200 instrument (GE).

Techniques: In Vitro, Binding Assay, Injection, Incubation, Control, Inhibition, Lysis, Phospho-proteomics, Immunoprecipitation